Raymond James Downgrades Alnylam Pharmaceuticals to Outperform, Lowers Price Target to $315
Benzinga Newsdesk 18 hours ago
Analyst RatingsNewsDowngradesPrice Target
Raymond James analyst Martin Auster downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Strong Buy to Outperform and lowers the price target from $420 to $315.
Raymond James analyst Martin Auster downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Strong Buy to Outperform and lowers the price target from $420 to $315.